Breaking News

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Learn More

Developing first-in-class and best-in-class therapeutics for obesity, diabetes, and other metabolic diseases

Learn More

RAPIDLY ADVANCING HARD-TO-ENGINEER ANTIBODIES

Explore

From precision antibody identification and optimization to tailored bispecifics and a cutting-edge masking technology

Learn More

License our discovery platform or collaborate with us to advance our high-value pipeline assets

Learn how we are advancing our pipeline of cardiometabolic and obesity therapeutics, developed and optimized with our AI Drug Discovery Platform

A Powerful Tech Stack for Validating Difficult Targets

Where collaboration fuels breakthroughs in drug discovery

Meet the team driving iBio’s powerful tech stack for drug discovery

See iBio's latest press releases

Recent Announcements

Get the most up-to-date company information

Learn More

Explore company updates, insights, and highlights

Learn More

A First-in-class Activin E Antibody Decreases Body Weight and Fat Mass in Diet-induced Obesity Mice

Learn More

For Investor inquiries, please visit our Investor Site